Hyperuricaemia and gout in New Zealand rural and urban Māori and non-Māori communities
No Thumbnail Available
Supplementary material
Other Title
Authors
Stamp, L. K.
Wells, J.E.
Pitama, S.G.
Faatoese, Allamanda F.
Doughty, Robert N.
Whalley, Gillian
Richards, A.M.
Cameron, Vicky A.
Wells, J.E.
Pitama, S.G.
Faatoese, Allamanda F.
Doughty, Robert N.
Whalley, Gillian
Richards, A.M.
Cameron, Vicky A.
Author ORCID Profiles (clickable)
Degree
Grantor
Date
2013-06
Supervisors
Type
Journal Article
Ngā Upoko Tukutuku (Māori subject headings)
Keyword
cohort studies
females
gout diagnosis
human beings
hyperuricemia diagnosis
males
middle aged
New Zealand ethnology
youth
females
gout diagnosis
human beings
hyperuricemia diagnosis
males
middle aged
New Zealand ethnology
youth
ANZSRC Field of Research Code (2020)
Citation
Stamp, L. K. (et al.). Hyperuricaemia and gout in New Zealand rural and urban Māori and non-Māori communities. Internal Medicine Journal (2013) Jun; Vol. 43 (6), pp. 678-84. An online version is available behind a wall but free with institutional access.
Abstract
Background: There are few current data on the prevalence of hyperuricaemia and gout in New Zealand, particularly among the indigenous Māori population.
Aims: To determine the prevalence of gout and hyperuricaemia in rural and urban Māori and non-Māori community samples and describe the treatment and comorbidities of participants with gout.
Methods: Participants aged 20-64 years were recruited by random selection from the electoral roll. Māori samples were selected from among those identified as being of Māori descent on the roll and who self-identified as being of Māori ethnicity at interview. Personal medical history, blood pressure, anthropometrics, fasting lipids, glucose, HbA1c and urate were recorded.
Results: There were 751 participants. Mean serum urate (SU) was 0.30 mmol/L (0.06-0.69 mmol/L). Māori had a significantly higher prevalence of hyperuricaemia (SU > 0.40 mmol/L) compared with non-Māori (17.0% vs 7.5%, P = 0.0003). A total of 57 participants had a history of gout, with a higher prevalence in Māori compared with non-Māori (10.3% vs 2.3%, P < 0.0001). Of the participants, 18/57 (31.6%) with gout were receiving urate-lowering therapy, but in 38.9%, SU was >0.36 mmol/L. Participants with gout were more likely to have metabolic syndrome, diabetes, cardiac disease or hypertension.
Conclusions: Gout and hyperuricaemia were more prevalent in Māori, and participants with gout were more likely to have comorbidities. There was not a higher overall adjusted cardiovascular disease risk in Māori participants with gout. Despite the high prevalence of gout, management remains suboptimal.
(© 2012 The Authors; Internal Medicine Journal © 2012 Royal Australasian College of Physicians.)
Publisher
Wiley-Blackwell Publishing Asia
Permanent link
Link to ePress publication
DOI
doi: 10.1111/imj.12062.
Copyright holder
Wiley-Blackwell Publishing Asia
Copyright notice
All rights reserved